Starpharma Holdings Ltd. (OTCMKTS:SPHRY – Get Free Report) shares dropped 0.4% during mid-day trading on Monday . The stock traded as low as $4.25 and last traded at $4.68. Approximately 2,614 shares changed hands during trading, an increase of 333% from the average session volume of 603 shares. The stock had previously closed at $4.70.
Starpharma Stock Performance
The business’s fifty day moving average price is $4.90 and its 200-day moving average price is $3.65.
Starpharma Company Profile
Starpharma is a clinical-stage biopharmaceutical company specializing in the development of dendrimer-based products across infectious disease, oncology and ophthalmology. Its proprietary dendrimer platform, DEP™ (Dendrimer Enhanced Products), enables precise molecular engineering to enhance drug delivery, targeting and safety profiles. The company’s lead product, VivaGel®, is a topical microbicide that has been approved in multiple markets for the treatment and prevention of bacterial vaginosis and is in clinical development for antiviral applications.
In addition to VivaGel, Starpharma is advancing pipeline candidates that leverage DEP technology to improve the performance of established and novel therapeutic agents.
Read More
- Five stocks we like better than Starpharma
- AirJoule Unveils Prime System, Clearing Path to Commercialization
- Copper Stocks Are Getting a Bigger Spotlight as Gold’s Rally Cracks
- Nike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets
- Uber’s Waymo Detour Tests the Stock’s Robotaxi Bull Case
Receive News & Ratings for Starpharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Starpharma and related companies with MarketBeat.com's FREE daily email newsletter.
